NEW YORK, Dec. 17, 2024 /PRNewswire/ -- Bria, the leading visual generative AI solution built for enterprise, and HP, the global technology leader and world's first digital printing company are proud ...
Release of interim data from the phase 3 study, using Bria-IMT + CPI for patients with metastatic breast cancer, expected in the 2nd half of 2025. Release of results from phase 1/2 Bria-BRES study, ...
Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patients Clinical benefit observed in 83% of evaluable patient ...
Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, ...
Bria, a generative artificial intelligence startup platform for developers that uses only licensed data, today announced that it has raised $40 million in early funding to scale up its technology for ...
BriaCell (BCTX) Therapeutics is pleased to showcase its survival and clinical benefit data in MBC patients, including those with CNS metastases, treated with the Bria-IMT plus CPI regimen. The data is ...
Leveraging Gen-AI and advanced digital printing, 9000 unique Nutella® labels were envisaged, pushing the boundaries of personalization and artistic expression through technology As a pioneer in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results